Last €52.43 EUR
Change Today +0.06 / 0.11%
Volume 571.6K
FME On Other Exchanges
Symbol
Exchange
OTC US
Xetra
Munich
New York
As of 3:45 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

fresenius medical care ag & (FME) Snapshot

Open
€52.31
Previous Close
€52.37
Day High
€52.89
Day Low
€52.22
52 Week High
01/29/14 - €54.38
52 Week Low
06/9/14 - €46.56
Market Cap
16.3B
Average Volume 10 Days
660.8K
EPS TTM
€3.50
Shares Outstanding
310.1M
EX-Date
05/16/14
P/E TM
19.8x
Dividend
€0.77
Dividend Yield
1.47%
Current Stock Chart for FRESENIUS MEDICAL CARE AG & (FME)

Related News

No related news articles were found.

fresenius medical care ag & (FME) Related Businessweek News

No Related Businessweek News Found

fresenius medical care ag & (FME) Details

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides renal dialysis products and services. It offers dialysis treatment, and related laboratory and diagnostic services through its network of 3,250 outpatient dialysis clinics in approximately 45 countries worldwide; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S. for the hospitalized ESRD patients and for patients suffering from acute kidney failure. The company also provides pharmacy services, such as delivery and supply of renal medications to patients at homes or to dialysis clinics directly; vascular access surgery services; and manufactures and distributes products for the treatment of end-stage renal disease (ESRD). In addition, it offers laboratory services that include blood, urine, and other bodily fluid testing services; and hemodialysis (HD) machines, modular components for dialysis machines, polysulfone dialyzers, bloodlines, HD solutions and concentrates, needles, connectors, machines for water treatment, data administration systems, dialysis chairs, phosphate binders, iron products, and other renal drug products. Further, the company provides peritoneal dialysis systems and solutions for continuous ambulatory peritoneal dialysis and automated peritoneal dialysis therapy; and adsorbers, which are filters used in other extracorporeal therapies; and distributes specific instruments for vascular access, as well as other supplies, such as bandages, clamps, and injections. It sells its products to clinics, hospitals, and specialized treatment clinics through direct sales forces, local sales forces, independent distributors, dealers, and sales agents. The company was founded in 1996 and is headquartered in Bad Homburg, Germany.

94,401 Employees
Last Reported Date: 07/31/14
Founded in 1996

fresenius medical care ag & (FME) Top Compensated Officers

Chairman of the Management Board for Freseniu...
Total Annual Compensation: $1.7M
Chief Financial Officer of Fresenius Medical ...
Total Annual Compensation: $1.0M
Chief Executive Officer of Fresenius Medical ...
Total Annual Compensation: $1.5M
Chief Executive Officer of Asia Pacific Divis...
Total Annual Compensation: $1.1M
Chief Executive Officer of Global Manufacturi...
Total Annual Compensation: $924.0K
Compensation as of Fiscal Year 2013.

fresenius medical care ag & (FME) Key Developments

Fresenius Medical Care AG & Co. KGAA Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Year 2014

Fresenius Medical Care AG & Co. KGAA announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported that its net revenue increased by 6% to $3,835 million compared to the second quarter of 2013. Operating income (EBIT) increased by 2% to $556 million compared to $544 million in the second quarter of 2013. Net income attributable to shareholders of the company was $234 million, a decrease of 11% compared to the corresponding number of $263 million for the second quarter of 2013. On an adjusted basis, net income attributable to shareholders of the company was $252 million. Diluted earnings per share (EPS) were $0.77, a decrease of 10% compared to the corresponding number for the second quarter of 2013. On an adjusted basis, EPS was $0.83. In the second quarter of 2014, the company generated $449 million in net cash provided by operating activities, a decrease of 14% compared to the corresponding figure of last year and representing 12% of revenue. A total of $218 million was spent for capital expenditures, net of disposals. Free cash flow was $231 million compared to $352 million in the second quarter of 2013. For the six months, the company reported that its net revenue increased by 5% to $7,398 million compared to the first half of 2013. Operating income (EBIT) decreased by 4% to $1,001 million compared to $1,038 million in the first half of 2013. For the first half of 2014, net income attributable to shareholders of the company was $439 million, down by 10% from the corresponding number of $488 million for the first half of 2013. On an adjusted basis, net income attributable to shareholders of the company was $457 million. Diluted earnings per share (EPS) were $1.45 against $1.59 a year ago. On an adjusted basis, EPS was $1.52. In the first half of 2014, the company generated $562 million in net cash provided by operating activities compared to $841 million for the same period in 2013, representing 8% of revenue. Purchases of property, plant and equipment was $419,259,000 against $333,642,000 a year ago. Free cash flow was $147 million compared to $522 million in the first half of 2013. For the year 2014, the company expects revenue to be at around $15.2 billion, translating into a growth rate of around 4%. This outlook excludes revenue of about $500 million from acquisitions. Net income attributable to shareholders of the company is expected to be unchanged between $1.0 billion and $1.05 billion in 2014. For 2014, the company expects to spend around $900 million on capital expenditures. Reflecting mainly the latest acquisitions the company now expects an acquisition spending of around $1.0 billion for fiscal year 2014. Operating income is $2.2 billion. Net cash provided by operating activities more than $1.5 billion and free cash flow in percentage of revenue is to be more than 4%. The company’s guidance remains unchanged, indicating the company anticipates a positive contribution to operating earnings of up to $60 million on a net basis for the year.

Fresenius Medical Care Mulls Acquisitions

Fresenius Medical Care AG & Co. KGAA (DB:FME) is looking for acquisitions. Mike Brosnan, Chief Financial Officer of Fresenius Medical Care AG & Co. KGAA said, "You'll continue to see us acquiring or investing in joint ventures in a number of markets around the world."

Fresenius Medical Care and Aetna Collaborate to Provide Coordinated Care Management for End Stage Renal Disease Patients

Fresenius Medical Care and Aetna announced a collaborative care model designed to improve the quality of care for Aetna's Medicare Advantage members who have end stage renal disease, while lowering health care costs. Fresenius Medical Care North America's (FMCNA) nationally-recognized care management program is accredited by the National Committee for Quality Assurance, and creates a new approach for the overall delivery of care focused squarely on the unique needs of dialysis patients. Through this collaboration, Aetna nurse case managers will work closely with FMCNA staff on quality and care management for Aetna Medicare Advantage members who are receiving care at an FMCNA clinic. Aetna and FMCNA will work together to improve the health outcomes of these patients by boosting adherence to best practices and treatment plans. This collaboration builds upon the relationship between Fresenius Medical Care and Aetna, who continue to expand a joint program to identify Aetna Medicare members with chronic kidney disease, and provide education, training and care management designed to ease what can be a difficult transition to dialysis or pre-transplant care.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FME:GR €52.43 EUR +0.06

FME Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $75.04 USD -0.76
CareFusion Corp $45.13 USD +0.08
DaVita HealthCare Partners Inc $73.65 USD -0.18
Terumo Corp ¥2,587 JPY -18.00
Toray Industries Inc ¥716.80 JPY -3.20
View Industry Companies
 

Industry Analysis

FME

Industry Average

Valuation FME Industry Range
Price/Earnings 19.9x
Price/Sales 1.4x
Price/Book 2.2x
Price/Cash Flow 20.4x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FRESENIUS MEDICAL CARE AG &, please visit www.fmc-ag.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.